This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Puma Biotech (PBYI) Stock Jumps 10.0%: Will It Continue to Soar?
by Zacks Equity Research
Puma Biotech (PBYI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Alnylam (ALNY) Posts Preliminary Q4 & Full-Year '23 Revenues
by Zacks Equity Research
Alnylam (ALNY) reports preliminary full-year and fourth-quarter 2023 net product revenues.
Ionis (IONS), AstraZeneca's Eplontersen Receives FDA Nod
by Zacks Equity Research
FDA approves Ionis (IONS) and partner AstraZeneca's (AZN) Wainua for treating ATTRv-PN. Ionis stock rises on this important milestone.
Apellis (APLS) Rides on Syfovre to Fuel Growth Amid Rivalry
by Zacks Equity Research
Apellis' (APLS) marketed products, Syfovre and Empaveli, continue to remain the growth drivers since launch. However, stiff competition in the target markets remains a woe.
Wall Street Analysts Think Alnylam (ALNY) Could Surge 35.08%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Alnylam (ALNY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues
by Zacks Equity Research
Alnylam (ALNY) reports better-than-expected third-quarter 2023 results, beating both earnings and sales estimates on the back of higher collaboration revenues.
Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales
by Zacks Equity Research
Agios' (AGIO) Q3 earnings beat estimates, but sales miss the same.
Alnylam (ALNY) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback
by Ekta Bagri
Acquisition and pipeline updates from Bristol Myers (BMY) and Akero Therapeutics (AKRO) are in focus in the biotech sector.
Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro
by Zacks Equity Research
Alnylam's (ALNY) label expansion-seeking application for Onpattro, to treat transthyretin-mediated amyloidosis with cardiomyopathy, gets the FDA's CRL on the grounds of insufficient data. The stock falls 5%.
Alnylam's (ALNY) Onpattro sNDA Gets FDA Advisory Committee Nod
by Zacks Equity Research
Alnylam (ALNY) receives a positive opinion from the FDA's advisory committee regarding the label expansion of patisiran to treat the cardiomyopathy of transthyretin-mediated amyloidosis.
Biotech Stock Roundup: MRNA's Vaccine Update, AMGN & HZNP Clear FTC Lawsuit & More
by Zacks Equity Research
Pipeline and regulatory updates from (MRNA) and Amgen (AMGN) are in focus in the biotech sector.
Alnylam's (ALNY) Zilebesiran Meets Goals in Mid-Stage Study
by Zacks Equity Research
Alnylam's (ALNY) mid-stage study of zilebesiran in the treatment of hypertension in patients at high cardiovascular risk meets primary and key secondary endpoints.
Why Is Qiagen (QGEN) Down 4.8% Since Last Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRISPR Therapeutics AG (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Regeneron (REGN) Gets FDA Nod for Higher Dose of Eylea
by Zacks Equity Research
Regeneron (REGN) obtains FDA approval for a higher dose of aflibercept injection under the brand name Eylea HD for various ophthalmology indications. The regulatory body also approves Veopoz.
Apellis (APLS) Focuses on Empaveli to Fuel Its Growth
by Zacks Equity Research
Apellis' (APLS) first marketed product, Empaveli, continues to be the growth driver since its launch. However, Syfovre faces some safety concerns post promising takeoff.
Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform
by Zacks Equity Research
Puma Biotechnology (PBYI) beats second-quarter earnings and sales estimates. Stock rises in after-hours.
Alnylam (ALNY) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Alnylam (ALNY) reports weaker-than-expected second-quarter results. The company also provides updates on its pipeline candidates, which are being developed in collaboration with other pharma bigwigs.
Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Agios (AGIO) reports narrower-than-expected loss in the second quarter of 2023. The revenues are in line with the Zacks Consensus Estimate.
Alnylam (ALNY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Alnylam (ALNY) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of -28.49% and 3.91%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Viatris' (VTRS) Q2 results are likely to be impacted by foreign exchange rates. Nevertheless, momentum in the branded business is likely to have continued.